Last reviewed · How we verify

BNT162b2 mRNA Covid-19 Vaccine — Competitive Intelligence Brief

BNT162b2 mRNA Covid-19 Vaccine (BNT162b2 mRNA Covid-19 Vaccine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

phase 2 Immunology Biologic Live · refreshed every 30 min

Target snapshot

BNT162b2 mRNA Covid-19 Vaccine (BNT162b2 mRNA Covid-19 Vaccine) — Ente Ospedaliero Ospedali Galliera. BNT162b2 mRNA Covid-19 Vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, prompting an immune response without causing the disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BNT162b2 mRNA Covid-19 Vaccine TARGET BNT162b2 mRNA Covid-19 Vaccine Ente Ospedaliero Ospedali Galliera phase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BNT162b2 mRNA Covid-19 Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/bnt162b2-mrna-covid-19-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: